Related Experiment Video
Updated: Jun 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Broad spectrum alkynyl inhibitors of T315I Bcr-Abl
Xianming Deng1, Sang Min Lim, Jianming Zhang
1Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, United States.
Abstract:
A series of alkyne-containing type II inhibitors with potent inhibitory activity of T315I Bcr-Abl has been identified. The most active compound 4 exhibits an EC(50) of less than 1 nM against wild-type Bcr-Abl and an EC(50) of 10 nM against T315I mutant but is broadly active against a number of other kinases.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Antiviral Nucleoside Inhibitors
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
